Durvalumab in DLBCL After Autologous Transplant

Inclusion Criteria: * Patients with any types of DLBCL (de novo or transformed), including double-hit lymphomas, grey zone lymphomas, double or triple expressor lymphomas, unclassifiable aggressive lymphoma types or aggressive lymphomas. * Lymphoma patients (as listed above) in first remission considered as high-risk and defined as lymphoma patients not achieving a complete first remission after induction treatment before subsequent ASCT; or patients in second remission considered as high-risk and defined as lymphoma patients relapsing within 12 months after first-line treatment or lymphoma patients not achieving a complete second remission after salvage treatment before subsequent ASCT. * ECOG 0-2 * Age 18-75 years * Female patients of child-bearing potential must have a negative pregnancy test (urine or serum) within 14 days prior to study treatment, and they must implement adequate measures (hormonal treatment p.o. or i.m., intra uterine surgical devices, or latex condoms) to avoid pregnancy during study treatment and for additional 12 months. * Patients must have given voluntary written informed consent. Exclusion Criteria: * Other types of malignant lymphomas * Previous treatment with antibodies against PD-(L)1 * Symptomatic CNS (Central Nervous System) involvement by lymphoma * Active infection requiring antibiotic/antifungal treatment * Lack of patient cooperation to allow study treatment as outlined in this protocol * Pregnancy or lactating female patients * Major …